[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
EGF receptor is slightly expressed in breast cancer without any sufficiently impact on patient outcome. Nevertheless determination of EGFR level represents a certain interest in order to orientate a targeted therapy notably in the case of hormone therapy resistance. Based on preclinical findings, preliminary clinical study results confirms in vitro observations about the possibility to encompass the hormonotherapy or anti-HER2 resistance. But, future large clinical trials are necessary to redefine a new strategy to treat breast cancer patients.
Magné
Nicolas
N
Laboratoire d'oncopharmacologie, Centre Antoine-Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 2.
Milano
Gérard
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011959:Receptors, Estradiol / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077143:Docetaxel; D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011959:Receptors, Estradiol; D043823:Taxoids; D000068878:Trastuzumab